Anticancer agent 320
Anticancer agent 320 is a potent broad-spectrum anticancer agent, with low toxicity toward noncancerous cells. Anticancer agent 320 induces cell cycle arrest, DNA double-strand breaks, and early apoptosis. Anticancer agent 320 disrupts mitochondrial function in cancer cells. Anticancer agent 320 inhibits proliferation of lung, colon, and breast cancer cells. Anticancer agent 320 can be used for the research of lung carcinoma, colon carcinoma, breast carcinoma.
For research use only. We do not sell to patients.
- Formula: C20H20FN3O3
- Molecular Weight:369.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anticancer agent 320 (compound 6g) (3.125-50 μM) inhibits the viability of MCF7, A549, and HCT116 cancer cells with IC50 values of 0.89, 1.02 and 1.29 μM, respectively, while showing minimal toxicity to MRC-5 cells (≥100 μM)[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces G1 phase arrest in HCT116 and A549 cells, and induces G2 phase accumulation in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces DNA double-strand breaks in A549 and HCT116 cells, but does not significantly increase DNA damage in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) potently induces early apoptosis in A549 cells, and modestly induces early apoptosis in HCT116 and MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits 3D spheroid growth in A549 cells and inhibits initial spheroid formation in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits long-term colony formation in A549, HCT116, and MCF7 cells, with the greatest effect observed in HCT116 cells[1].
Anticancer agent 320 exhibits favourable binding interactions with key cancer-related proteins, including the highest affinity for MAPK8 with a docking score of -7.872 kcal/mol and MM-GBSA binding free energy of -55.11 kcal/mol[1].
Anticancer agent 320 reduces membrane potential in A549, HCT116, and MCF7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, HCT116, MCF7
-
Concentration:0.89 (MCF7), 1.02 (A549) and 1.29 μM (HCT116)
-
Incubation Time:72 h
-
Result:Increased G1 phase occupancy to 43.1% and reduced S phase to 31.1% in HCT116 cells, indicating G1 phase arrest.
Increased G1 phase occupancy to 62.6% and reduced S phase to 18.8% in A549 cells, indicating G1 phase arrest.
Increased G1 phase to 69.6% and significantly increased G2 phase to 30.3% in MCF7 cells, indicating a unique G2 phase accumulation profile distinct from the G1 arrest seen in other cell lines.
-
Cell Line:A549, HCT116, MCF7
-
Concentration:0.89 (MCF7), 1.02 (A549) and 1.29 μM (HCT116)
-
Incubation Time:72 h
-
Result:Induced early apoptosis in 77.83% of A549 cells, leaving only 10.07% of cells viable.
Induced early apoptosis in 14.98% of HCT116 cells, with 70.58% of cells remaining viable.
Induced early apoptosis in 23.1% of MCF7 cells.
Chemical Information
-
Molecular Weight 369.39
-
Formula C20H20FN3O3
-
SMILES
CCC(N1C(C(C(NCC2=NC=CC=C2)=O)=C(C3=CC(F)=CC=C31)O)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz